Targeting NO-cGMP-PKG-ERK signaling pathway may represent an interesting approach for the development of new drugs in the treatment of memory dysfunctions occurring in neurodegenerative and psychiatric diseases, among others Alzheimer’s disease and dementia. The gene discussed is PRKG1; the disease is early-onset autosomal dominant Alzheimer disease.